Eduardo Terán: mBC and PIK3CA mutations in tissue and plasma
Eduardo Terán, Medical Oncologist, shared a post on X:
“Just published!
Excited to share our latest research on mBC and PIK3CA mutations in tissue and plasma. Crucial role of PIK3CA analysis in ctDNA Special thanks to my mentors César A. Rodríguez, RebecaLm, IBSAL.
PIK3CAm are present in 38.5% of HR+/HER2- BC 70.3% correlation rate between tissue & plasma discordant result in 29.7% PIK3CAm in tissue but not in plasma. Improving the sensitivity of the techniques is urgently needed.
Worse mPFS with cyclin inhibitors in patients with PIK3CAm exon 9 vs PIK3CAm exon 20 (9.7m vs 30.3m; HR = 2.84, p = 0.024). Prospective validation is required. Window of opportunity for exon 9 mutated patients, upfront triple therapy.
PIK3CAm in plasma are associated with shorter mPFS (12.4m vs 29.3m; HR = 2.4; p = 0.08) PIK3CA evaluation in tissue remains the diagnostic method of choice.”
PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2− breast cancer
Authors: Eduardo Terán, Rebeca Lozano, César A. Rodríguez, Mar Abad, Luis Figuero, José Antonio Muñoz, Belén Cigarral, Aline Rodrígues, Magdalena Sancho, M. Asunción Gómez, Daniel Morchón, Juan Carlos Montero, José María Sayagués, M. Dolores Ludeña, Emilio Fonseca.
Source: Eduardo TB/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023